Acute Myeloid Leukemia Market Revenue, Growth, Demand, Challenges and Future Investment Opportunities Till 2034
Acute Myeloid Leukemia Market Growth, Size, Trends Analysis - By Disease, By Treatment, By Route of Administration, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Mar-2025 | Report ID: HLCA2597 | Pages: 1 - 259 | Formats*: |
| Category : Healthcare | |||
Acute Myeloid Leukemia Market Introduction and Overview
According to SPER Market Research, the Global Acute Myeloid Leukemia Market is estimated to reach USD 9.73 billion by 2034 with a CAGR of 10.86%.
The report includes an in-depth analysis of the Global Acute Myeloid Leukemia Market, including market size and trends, Interface mix, Applications, and supplier analysis.
Acute Myeloid Leukemia (AML) is an aggressive blood cancer characterized by the rapid proliferation of abnormal myeloid cells in the bone marrow, leading to impaired blood cell production. AML primarily affects older adults but can occur at any age, with risk factors including genetic mutations, prior chemotherapy, and exposure to radiation or harmful chemicals. The market for AML treatment is growing due to increasing disease prevalence, advancements in targeted therapies, and a rising focus on personalized medicine. Innovations in immunotherapy, stem cell transplantation, and precision oncology are improving patient outcomes. However, challenges such as high treatment costs, limited long-term survival rates, disease relapse, and the toxicity of existing therapies continue to hinder effective management and widespread treatment accessibility.
By Disease Insights: The myeloblastic leukemia sector held the biggest market share, driven by the high incidence and prevalence of this disease type, which creates a substantial demand for effective therapies. The ongoing creation of new treatments and the advancement of current ones also contribute to the market segment's robust size. To assess targeted treatment combinations for acute myeloid leukemia and myelodysplastic syndromes based on patients' genetic profiles, for example, the National Institutes of Health initiated a precision medicine clinical study in the United States in October 2024. There is clear evidence of additional financing for research.
By Treatment Insights: The chemotherapy segment held the most share, because of its wide range of applications across different subtypes and demonstrated effectiveness in attaining remission, particularly during induction therapy, chemotherapy has continued to be the principal treatment option for AML. Furthermore, older patients and those with significant comorbidities have seen improved outcomes due to the strategic integration of chemotherapy with newer agents like low-dose cytarabine and glasdegib. This has ensured chemotherapy's continued relevance and significant market share in AML treatment strategies.
By Route of Administration Insights: The parenteral route segment led the market, mostly because the most potent chemotherapies, such as cytarabine and medications based on anthracyclines, were administered intravenously. Rapid bloodstream absorption made possible by this technique permits precise dosage that efficiently targets cancer cells. Parenteral administration is essential for the first stages of treatment that aim to achieve remission because of the urgency of AML. This segment's crucial significance in efficient AML care was further highlighted in 2023 when the FDA approved novel medication combinations.
By End Use Insights: The hospitals and clinics segment held the greatest share. This is mostly because AML is a complicated disease that necessitates advanced facilities, specialist medical personnel, and sophisticated diagnostic technologies for efficient therapy management. Clinics and hospitals are prepared to offer complete care, including stem cell transplants and high-dose chemotherapy, which are frequently required in AML treatment regimens.
By Regional Insights: The North American acute myeloid leukemia therapy market led the global market. The treatment of AML in North America is being revolutionized by targeted treatments and immunotherapies, which have demonstrated encouraging outcomes in clinical trials. With new medicines like CAR-T cell therapy and BiTE antibodies providing hope for refractory cases, precision medicine places a strong emphasis on customizing medications to each patient's unique genetic profile. Significant differences in access to leukemia care were found in a 2024 study conducted by the Alliance for Leukaemia’s in Mexico.
Market Competitive Landscape
The market for Acute Myeloid Leukemia is very competitive. Companies are focusing on product innovation, developing screws with improved materials and designs to cater to evolving surgical needs. Some of the prominent players in Global Acute Myeloid Leukemia Market are Astellas Pharma Inc., Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY LIMITED, Jazz Pharmaceuticals plc, Merck, Novartis, Otsuka Pharmaceuticals Co. Ltd., Pfizer Inc., Rigel Pharmaceuticals Inc., Sanofi.
Recent Developments:
- In December 2024: The QuANTUM-Wild Phase 3 trial, which began in Japan and the United States, is evaluating VANFLYTA's efficacy in combination with chemotherapy for patients with newly diagnosed FLT3-ITD negative acute myeloid leukemia.
- In October 2024: MilliporeSigma announced a USD 76 million expansion of their ADC production capabilities in St. Louis, Missouri, which would triple capacity to satisfy worldwide demand and create 170 new jobs.
- In September 2024: Rigel expanded its cooperation with Kissei by offering them exclusive rights to develop and commercialize REZLIDHIA in Japan, Korea, and Taiwan in exchange for a USD 10 million upfront payment.
- In April 2024: Actinium announced the findings of the Phase 3 SIERRA trial for Iomab-B, which demonstrated a survival advantage in patients with high-risk relapsed or refractory acute myeloid leukemia with TP53 mutations. These findings were accepted as oral presentations at the 50th European Bone Marrow Transplant Annual Meeting.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Disease, By Treatment, By Route of Administration, By End Use. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | Astellas Pharma Inc., Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY LIMITED, Jazz Pharmaceuticals plc, Merck, Novartis, Otsuka Pharmaceuticals Co. Ltd., Pfizer Inc., Rigel Pharmaceuticals Inc., Sanofi. |
Key Topics Covered in the Report
- Global Acute Myeloid Leukemia Market Size (FY’2025-FY’2034)
- Overview of Global Acute Myeloid Leukemia Market
- Segmentation of Global Acute Myeloid Leukemia Market By Disease (Myeloblastic Leukemia, Myelomonocytic Leukemia, Promyelocytic Leukemia, Monocytic Leukemia and Other Diseases)
- Segmentation of Global Acute Myeloid Leukemia Market By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatments)
- Segmentation of Global Acute Myeloid Leukemia Market By Route of Administration (Parenteral and Oral)
- Segmentation of Global Acute Myeloid Leukemia Market By End Use (Hospitals and Clinics, Specialty Centers, Homecare Setting and Ambulatory Care Centers)
- Statistical Snap of Global Acute Myeloid Leukemia Market
- Expansion Analysis of Global Acute Myeloid Leukemia Market
- Problems and Obstacles in Global Acute Myeloid Leukemia Market
- Competitive Landscape in the Global Acute Myeloid Leukemia Market
- Details on Current Investment in Global Acute Myeloid Leukemia Market
- Competitive Analysis of Global Acute Myeloid Leukemia Market
- Prominent Players in the Global Acute Myeloid Leukemia Market
- SWOT Analysis of Global Acute Myeloid Leukemia Market
- Global Acute Myeloid Leukemia Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPERs internal database2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Acute Myeloid Leukemia Market Manufacturing Base Distribution, Sales Area, Interface Type6.2. Mergers & Acquisitions, Partnerships, Interface Launch, and Collaboration in Global Acute Myeloid Leukemia Market
7. Global Acute Myeloid Leukemia Market, By Disease 2021-2034 (USD Million)
7.1. Myeloblastic Leukemia7.2. Myelomonocytic Leukemia7.3. Promyelocytic Leukemia7.4. Monocytic Leukemia7.5. Other Diseases
8. Global Acute Myeloid Leukemia Market, By Treatment 2021-2034 (USD Million)
8.1. Chemotherapy8.2. Targeted Therapy8.3. Immunotherapy8.4. Other Treatments
9. Global Acute Myeloid Leukemia Market, By Route of Administration 2021-2034 (USD Million)
9.1. Parenteral9.2. Oral
10. Global Acute Myeloid Leukemia Market, By End Use 2021-2034 (USD Million)
10.1. Hospitals and Clinics10.2. Specialty Centers10.3. Homecare Setting10.4. Ambulatory Care Centers
11. Global Acute Myeloid Leukemia Market Forecast, 2021-2034 (USD Million)
11.1. Global Acute Myeloid Leukemia Market Size and Market Share
12. Global Acute Myeloid Leukemia Market, By Region, 2021-2034 (USD Million)
12.1. Asia-Pacific
12.1.1. Australia12.1.2. China12.1.3. India12.1.4. Japan12.1.5. South Korea12.1.6. Rest of Asia-Pacific
12.2. Europe
12.2.1. France12.2.2. Germany12.2.3. Italy12.2.4. Spain12.2.5. United Kingdom12.2.6. Rest of Europe
12.3. Middle East and Africa
12.3.1. Kingdom of Saudi Arabia12.3.2. United Arab Emirates12.3.3. Qatar12.3.4. South Africa12.3.5. Egypt12.3.6. Morocco12.3.7. Nigeria12.3.8. Rest of Middle-East and Africa
12.4. North America
12.4.1. Canada12.4.2. Mexico12.4.3. United States
12.5. Latin America
12.5.1. Argentina12.5.2. Brazil12.5.3. Rest of Latin America
13. Company Profile
13.1. Astellas Pharma Inc.
13.1.1. Company details13.1.2. Financial outlook13.1.3. Interface summary13.1.4. Recent developments
13.2. Bristol-Myers Squibb Company
13.2.1. Company details13.2.2. Financial outlook13.2.3. Interface summary13.2.4. Recent developments
13.3. DAIICHI SANKYO COMPANY LIMITED
13.3.1. Company details13.3.2. Financial outlook13.3.3. Interface summary13.3.4. Recent developments
13.4. Jazz Pharmaceuticals Plc
13.4.1. Company details13.4.2. Financial outlook13.4.3. Interface summary13.4.4. Recent developments
13.5. Merck
13.5.1. Company details13.5.2. Financial outlook13.5.3. Interface summary13.5.4. Recent developments
13.6. Novartis
13.6.1. Company details13.6.2. Financial outlook13.6.3. Interface summary13.6.4. Recent developments
13.7. Otsuka Pharmaceuticals Co. Ltd.
13.7.1. Company details13.7.2. Financial outlook13.7.3. Interface summary13.7.4. Recent developments
13.8. Pfizer Inc.
13.8.1. Company details13.8.2. Financial outlook13.8.3. Interface summary13.8.4. Recent developments
13.9. Rigel Pharmaceuticals Inc.
13.9.1. Company details13.9.2. Financial outlook13.9.3. Interface summary13.9.4. Recent developments
13.10. Sanofi
13.10.1. Company details13.10.2. Financial outlook13.10.3. Interface summary13.10.4. Recent developments
14. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Acute Myeloid Leukemia Market size is USD 9.73 billion from 2025 to 2034.
Acute Myeloid Leukemia Market is covered By Product, By Function, By Application, By End-User.
The North America is anticipated to have the highest Market share in the Acute Myeloid Leukemia Market.
The key players in the Market include Companies Covered Astellas Pharma Inc., Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY LIMITED, Jazz Pharmaceuticals plc, Merck, Novartis, Otsuka Pharmaceuticals Co. Ltd., Pfizer Inc., Rigel Pharmaceuticals Inc., Sanofi.
Acute Myeloid Leukemia (AML) is an aggressive blood cancer characterized by the rapid proliferation of abnormal myeloid cells in the bone marrow, leading to impaired blood cell production. AML primarily affects older adults but can occur at any age, with risk factors including genetic mutations, prior chemotherapy, and exposure to radiation or harmful chemicals.
Acute Myeloid Leukemia Market is projected to reach USD 9.73 billion by 2034, growing at a CAGR of 10.86% during the forecast period.
Acute Myeloid Leukemia Market grew in Market size from 2025. The Market is expected to reach USD 9.73 billion by 2034, at a CAGR of 10.86% during the forecast period.
Acute Myeloid Leukemia Market CAGR of 10.86% during the forecast period.
You can get the sample pages by clicking the link - Click Here
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
